CN117530894A - 一种能够抑制幽门螺杆菌的漱口水及其制备方法 - Google Patents
一种能够抑制幽门螺杆菌的漱口水及其制备方法 Download PDFInfo
- Publication number
- CN117530894A CN117530894A CN202410026382.9A CN202410026382A CN117530894A CN 117530894 A CN117530894 A CN 117530894A CN 202410026382 A CN202410026382 A CN 202410026382A CN 117530894 A CN117530894 A CN 117530894A
- Authority
- CN
- China
- Prior art keywords
- mouthwash
- helicobacter pylori
- chinese medicine
- traditional chinese
- inhibiting helicobacter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002324 mouth wash Substances 0.000 title claims abstract description 62
- 229940051866 mouthwash Drugs 0.000 title claims abstract description 58
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 49
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 49
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000001488 sodium phosphate Substances 0.000 claims abstract description 22
- 229910000162 sodium phosphate Inorganic materials 0.000 claims abstract description 22
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims abstract description 22
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 21
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 21
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000008367 deionised water Substances 0.000 claims abstract description 19
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 19
- 240000007817 Olea europaea Species 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 238000004090 dissolution Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 240000007087 Apium graveolens Species 0.000 claims abstract description 7
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims abstract description 7
- 235000010591 Appio Nutrition 0.000 claims abstract description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 7
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 6
- 235000011477 liquorice Nutrition 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 22
- 235000006708 antioxidants Nutrition 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 239000011812 mixed powder Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 235000002725 Olea europaea Nutrition 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 3
- 229940010454 licorice Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000000214 mouth Anatomy 0.000 abstract description 17
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010019375 Helicobacter infections Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 206010006326 Breath odour Diseases 0.000 description 3
- 208000032139 Halitosis Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000020670 canker sore Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- -1 coumarin, polysaccharides Chemical class 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010056663 Gastric infection Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- TURHTASYUMWZCC-UHFFFAOYSA-N Olaquindox [BAN:INN] Chemical compound C1=CC=C2N([O-])C(C)=C(C(=O)NCCO)[N+](=O)C2=C1 TURHTASYUMWZCC-UHFFFAOYSA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950010210 olaquindox Drugs 0.000 description 1
- 229940114496 olive leaf extract Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cosmetics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种漱口水,具体涉及一种能够抑制幽门螺杆菌的漱口水及其制备方法,所述漱口水,由以下质量百分比的组分组成:中药提取物5‑20%、透明质酸1‑4%、抗氧化剂0.2‑1%、磷酸钠0.2‑0.8%、奥拉氟0.05‑0.15%、乙醇5‑15%,余量为去离子水;所述中药提取物由甘草、橄榄叶和香芹制成。所述漱口水的制备方法为按配方量将中药提取物、透明质酸、抗氧化剂和磷酸钠加入到去离子水中混合均匀;奥拉氟加入乙醇中搅拌溶解,然后将两者充分混合,得漱口水。本发明的漱口水可以抑制口腔内幽门螺杆菌的生长和繁殖,降低接触后感染幽门螺杆菌的风险,提高口腔免疫力,维持口腔健康。
Description
技术领域
本发明涉及漱口水及其制备方法,更具体地说,涉及一种能够抑制幽门螺杆菌的漱口水。本发明还涉及该漱口水的制备方法。
背景技术
幽门螺杆菌是一种革兰氏阴性菌,是对人类健康造成严重威胁的细菌,其感染是慢性胃炎、消化性溃疡、胃粘膜相关淋巴组织、淋巴瘤等疾病的主要病因之一。目前,临床上主要采用抗生素-离子泵抑制剂-铋剂等三联疗法来治疗幽门螺杆菌感染,但长期使用多种药物易产生耐药性,且副作用较大。
幽门螺杆菌是一种经口传播的传染病,口腔幽门螺杆菌是胃幽门螺杆菌的重要贮存库。幽门螺杆菌也是一种对口腔健康有害的细菌,其感染会导致口臭、口腔炎症等问题。一方面,因为一旦感染了幽门螺杆菌就会在我们胃里产生尿酸酶,这种物质会分解出胺类物质为自己提供生存条件,当产生的氨气量过多,会通过我们的嘴巴排体外,从而导致出现口臭;另一方面,通过口腔进入的幽门螺杆菌在短时间内会存活于口腔中,附着在牙齿上,久而久之就会引起口腔感染,加重胃部感染程度。人在饭后,口腔pH值在5.5左右,此时若接触幽门螺杆菌便是感染最好的时机,若漱口水使用的及时,就能有效预防口腔的接触感染。目前,市场上存在一些牙膏、漱口水等口腔制品声称具有抑制幽门螺杆菌的作用,但是效果并不理想。因此,开发一种能够有效抑制幽门螺杆菌的漱口水对于保护口腔健康具有重要意义。
发明内容
针对上述技术问题,本发明的第一个目的在于提供一种能够抑制幽门螺杆菌的漱口水,该漱口水能够有效抑制口腔内细菌,特别是幽门螺杆菌的生长和繁殖,也可降低因接触发生口腔幽门螺杆菌感染的风险。
本发明的第二个目的在于提供一种能够抑制幽门螺杆菌的漱口水的制备方法,该方法更有利于保留原料中的有效成分,制备的漱口水疗效更好。
本发明第一个目的通过以下技术方案来实现:一种能够抑制幽门螺杆菌的漱口水,由以下质量百分比的组分组成:中药提取物5-20%、透明质酸1-4%、抗氧化剂0.2-1%、磷酸钠0.2-0.8%、奥拉氟0.05-0.15%、乙醇5-15%,余量为去离子水;所述中药提取物由甘草、橄榄叶和香芹制成。
进一步地,所述中药提取物按照质量份数由甘草10-15份、橄榄叶10-15份和香芹12-18份制成。
进一步地,所述中药提取物按照质量份数由甘草10-12份、橄榄叶10-12份和香芹15-18份制成。
进一步地,所述抗氧化剂为维生素C或维生素E中的一种或两种。
进一步地,所述漱口水的pH值为6.6-7.1。
本发明的第二个目的通过以下技术方案来实现:上述能够抑制幽门螺杆菌的漱口水的制备方法,包括下述步骤:
(1)将干燥的甘草、橄榄叶和香芹粉碎,得到混合粉末;
(2)将混合粉末放入提取设备中,加入10-20倍粉末量的乙醇水溶液提取3-4小时,得提取液;
(3)将提取液过滤,滤渣加入步骤(2)中相同的乙醇水溶液提取1.5-2小时,再次过滤,合并两次滤液;
(4)将合并的两次滤液真空干燥,得到中药提取物;
(5)按配方量将中药提取物、透明质酸、抗氧化剂和磷酸钠加入到去离子水中混合均匀;奥拉氟加入乙醇中搅拌溶解,然后将两者充分混合,得漱口水。
进一步地,所述步骤(1)中,粉末为30-45μm的颗粒状粉末
进一步地,所述步骤(2)中,提取温度为80-85℃。
进一步地,所述步骤(2)中,乙醇水溶液的浓度为35-45%。
进一步地,所述步骤(4)中真空干燥的温度为55-65℃。
与现有技术相比,本发明具有的有益效果为:
1.本发明的一种能够抑制幽门螺杆菌的漱口水,可以抑制口腔内幽门螺杆菌的生长和繁殖,降低接触后感染幽门螺杆菌的风险,提高口腔免疫力,维持口腔健康。将本发明漱口水与三联疗法联合治疗,同时治疗口腔和胃部,大大提高幽门螺杆菌感染的治愈率,降低复发可能性。
2.本发明的漱口水含有香芹提取物,其主要成分包括挥发油、佛手柑内脂酯和有机酸等,具有清热除烦、利水消肿,特别是其中的挥发油和有机酸起到抑制细菌生长和繁殖的作用;
橄榄叶提取物,具有多种生物活性,起到抗氧化、抗炎的作用,对于已经引起的口腔炎症起到很好的缓解作用;
甘草提取物,其化学成分包括黄酮类、皂苷类、生物碱、氨基酸类、香豆素类、多糖类等,从甘草中分离提取出的主要活性成分,具有抗氧化、抗炎、免疫调节、抗溃疡、抗病毒、抗肿瘤、抗抑郁、镇痛、保肝、抗动脉粥样硬化等多种药理作用,具有清热解毒、增强免疫力、调和诸药的功效,此外,甘草酸还能够修复口腔黏膜和胃粘膜,抑制幽门螺杆菌的生长,还能够起到甜味剂的作用,大大改善了漱口水的舒适度。
透明质酸,是一种天然的保湿成分,具有很好的保湿效果,在本发明的漱口水中添加透明质酸,起到保湿、润滑的作用,使漱口后的口腔更加舒适,
抗氧化剂用于消除口腔内的自由基,保护口腔黏膜,对于抑制幽门螺杆菌的生长有至关重要的作用;
磷酸钠作为清洁剂,能够清除口腔中细菌和污垢,幽门螺杆菌在口腔中大多寄生于牙垢中,磷酸钠的使用可以破坏幽门螺杆菌在口腔中的生存环境;同时,磷酸钠还起到调节漱口水pH值的作用,使漱口水得酸碱度更加适应口腔环境;
奥拉氟,一方面可以提高牙齿对幽门螺杆菌酸性侵蚀的抵抗力,另一方面,与中药提取物相互配合,起到抑制幽门螺杆菌的作用。
诸药合用,达到了抑制幽门螺杆菌的功效。
3.本发明的漱口水的制备方法,以适当时间和温度进行中药组合物的提取,更有利于保留药物成分,制备方法简单,疗效更好。
具体实施方式
下面结合具体实施方式,对本发明的技术方案作进一步的详细说明,但不构成对本发明的任何限制。
实施例1
将干燥的甘草1000g、橄榄叶1000g和香芹1500g粉碎至30-45μm,到混合粉末;将混合粉末放入提取设备中,加入10倍粉末量的45%体积浓度的乙醇水溶液浸泡两个小时,在80℃下超声提取3小时,得提取液;将提取液过滤,滤渣中加入上述10倍粉末量的相同的乙醇水溶液提取1.5小时,再次过滤,合并两次得到的滤液;两次滤液在60℃下真空干燥浓缩,得到中药提取物;
按照配方量:中药提取物5%、透明质酸1%、维生素C 0.2%、磷酸钠0.8%、奥拉氟0.15%、乙醇5%以及87.85%去离子水。将中药提取物、透明质酸、抗氧化剂和磷酸钠加入到去离子水中混合均匀;奥拉氟加入乙醇中搅拌溶解,然后将两者充分混合,得漱口水。
实施例2
将干燥的甘草1000g、橄榄叶1500g和香芹1800g粉碎至30μm,到混合粉末;将混合粉末放入提取设备中,加入20倍粉末量的45%体积浓度的乙醇水溶液浸泡两个小时,在85℃下超声提取4小时,得提取液;将提取液过滤,滤渣中加入上述20倍粉末量的相同的乙醇水溶液提取2小时,再次过滤,合并两次得到的滤液;两次滤液在5℃下真空干燥浓缩,得到中药提取物;
按照配方量:中药提取物20%、透明质酸1%、抗氧化剂(维生素E)1%、磷酸钠0.2%、奥拉氟0.05%、乙醇5%以及72.75%去离子水。将中药提取物、透明质酸、抗氧化剂和磷酸钠加入到去离子水中混合均匀;奥拉氟加入乙醇中搅拌溶解,然后将两者充分混合,得漱口水。
实施例3
将干燥的甘草1200g、橄榄叶1200g和香芹1800g粉碎至30-45μm,到混合粉末;将混合粉末放入提取设备中,加入15倍粉末量的35%体积浓度的乙醇水溶液浸泡两个小时,在85℃下超声提取3小时,得提取液;将提取液过滤,滤渣中加入上述15倍粉末量的相同的乙醇水溶液提取1.5小时,再次过滤,合并两次得到的滤液;两次滤液在55℃下真空干燥浓缩,得到中药提取物;
按照配方量:中药提取物10%、透明质酸4%、抗氧化剂(维生素C)0.2%、磷酸钠0.8%、奥拉氟0.1%、乙醇10%以及74.9%去离子水。将中药提取物、透明质酸、抗氧化剂和磷酸钠加入到去离子水中混合均匀;奥拉氟加入乙醇中搅拌溶解,然后将两者充分混合,得漱口水。
实施例4
将干燥的甘草1500g、橄榄叶1000g和香芹1600g粉碎至30-45μm,到混合粉末;将混合粉末放入提取设备中,加入15倍粉末量的40%体积浓度的乙醇水溶液浸泡两个小时,在80℃下超声提取3小时,得提取液;将提取液过滤,滤渣中加入上述15倍粉末量的相同的乙醇水溶液提取2小时,再次过滤,合并两次得到的滤液;两次滤液在55℃下真空干燥浓缩,得到中药提取物;
按照配方量:中药提取物15%、透明质酸2%、抗氧化剂(维生素E)0.5%、磷酸钠0.5%、奥拉氟0.10%、乙醇10%以及71.9%去离子水。将中药提取物、透明质酸、抗氧化剂和磷酸钠加入到去离子水中混合均匀;奥拉氟加入乙醇中搅拌溶解,然后将两者充分混合,得漱口水。
对比例1
按照配方量:透明质酸1%、抗氧化剂(维生素C)0.2%、磷酸钠0.8%、奥拉氟0.15%、乙醇5%以及92.85%去离子水。将透明质酸、抗氧化剂和磷酸钠加入到去离子水中混合均匀;奥拉氟加入乙醇中搅拌溶解,然后将两者充分混合,得漱口水。
对比例2
按照配方量:中药提取物5%、透明质酸1%、抗氧化剂(维生素C)0.2%、磷酸钠0.8%、乙醇5%以及88%去离子水。将中药提取物、透明质酸、抗氧化剂和磷酸钠、乙醇加入到去离子水中混合均匀,得漱口水。
其他步骤与实施例1相同。
幽门螺杆菌抑菌实验
将实施例1-4和对比例1-2得到的漱口水作为实验组,对照组的漱口水为不含有奥拉氟和中药提取物的漱口水,即配方量为质量百分比为透明质酸1%、抗氧化剂0.2%、磷酸钠0.8%、乙醇5%以及93%去离子水的漱口水。
参照行业标准《QBT 2738日化产品抗菌抑菌效果的评价方法》,对以上各组的漱口水进行幽门螺杆菌的抑菌实验,实验结果如表1所示,所示实验数据为平均值。
表1 幽门螺杆菌抑菌实验结果
由表1数据可知,实施例1~4及对比例1、对比例2均对幽门螺杆菌均有抑制效果。但是对比例1不添加中药提取物、对比例2不添加奥拉氟,都起不到很好的抑制幽门螺杆菌效果。因此,本发明中的中药提取物与奥拉氟起到了协同作用,对幽门螺杆菌有很强的抑制效果。
应用例1
为考查本发明漱口水的功效,与医院联合实验,实验如下:
将幽门螺杆菌感染的口臭和口腔溃疡患者随机分成3组,每组25人,分别使用本发明实施例1漱口水、对比例1漱口水和普通漱口水(氯化钠),每天使用3次,观察患者的康复情况,结果如表2所示。
表2 不同分组患者每天的康复人数
普通漱口水在清洁口腔之后并不能帮助口腔溃疡创面的愈合,对比例1漱口水有一定的愈合作用,但显效慢。从试验数据中可以发现,对照组漱口水对口腔溃疡的愈合期在6天以上,而且愈合率很低。本发明实施例1的漱口水在使用第3天的时候,口腔溃疡便开始愈合,一周以内便可痊愈。
应用例2
实施例4对幽门螺杆菌感染者联合三联疗法的治疗效果
选取242例HP感染患者,分成两组,每组121例,每组均经C13吹气法测定为阳性(测定数值为大于10.0,标准值为4),以至享(HP染色试剂盒)测定为阳性至强阳性。对照组用奥美拉唑肠溶胶囊20mg,1日2次,克拉霉素分散片250mg,1日2次,阿莫西林胶囊500mg,6~8小时一粒,胶体果胶铋胶囊50mg一次3粒,一日4次。治疗组用以上三联疗法,并配合使用实施例4的漱口水,一日三次,使用时以舌头在口腔搅动30秒后吐出。用完后30分钟不得饮水或进餐。连续使用3周。3周后至享(HP染色试剂盒)检查。停药1个月后再次经C13吹气检查。治疗组症状缓解时间为(4.8 ± 2.7)d,明显短于对照组的(9.7 ±2.1)d,差异有统计学意义(P<0 .01)。对照组三个月后复发率33.47%,治疗组三个月后复发率3.39%(P<0.05)。可见,将本发明漱口水与三联疗法联合治疗,同时治疗口腔和胃部,大大提高幽门螺杆菌感染的治愈率,降低复发可能性。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其它的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (10)
1.一种能够抑制幽门螺杆菌的漱口水,其特征在于,由以下质量百分比的组分组成:中药提取物5-20%、透明质酸1-4%、抗氧化剂0.2-1%、磷酸钠0.2-0.8%、奥拉氟0.05-0.15%、乙醇5-15%,余量为去离子水;所述中药提取物由甘草、橄榄叶和香芹制成。
2.根据权利要求1所述的能够抑制幽门螺杆菌的漱口水,其特征在于,所述中药提取物按照质量份数由甘草10-15份、橄榄叶10-15份和香芹12-18份制成。
3.根据权利要求2所述的能够抑制幽门螺杆菌的漱口水,其特征在于,所述中药提取物按照质量份数由甘草10-12份、橄榄叶10-12份和香芹15-18份制成。
4.根据权利要求1或2或3所述的能够抑制幽门螺杆菌的漱口水,其特征在于,所述抗氧化剂为维生素C或维生素E中的一种或两种。
5.根据权利要求4所述的能够抑制幽门螺杆菌的漱口水,其特征在于,所述漱口水的pH值为6.6-7.1。
6.根据权利要求1所述的能够抑制幽门螺杆菌的漱口水的制备方法,其特征在于,包括以下述步骤:
(1)将干燥的甘草、橄榄叶和香芹粉碎,得到混合粉末;
(2)将混合粉末放入提取设备中,加入10-20倍粉末量的乙醇水溶液提取3-4小时,得提取液;
(3)将提取液过滤,滤渣加入步骤(2)中相同的乙醇水溶液提取1.5-2小时,再次过滤,合并两次滤液;
(4)将合并的两次滤液真空干燥,得到中药提取物;
(5)按配方量将中药提取物、透明质酸、抗氧化剂和磷酸钠加入到去离子水中混合均匀;奥拉氟加入乙醇中搅拌溶解,然后将两者充分混合,得漱口水。
7.根据权利要求6所述的能够抑制幽门螺杆菌的漱口水的制备方法,其特征在于,所述步骤(1)中,粉末为30-45μm的颗粒状粉末。
8.根据权利要求6所述的能够抑制幽门螺杆菌的漱口水的制备方法,其特征在于,所述步骤(2)中,提取温度为80-85℃。
9. 根据权利要求6所述的能够抑制幽门螺杆菌的漱口水的制备方法 ,其特征在于,所述步骤(2)中,乙醇水溶液的浓度为35-45%。
10. 根据权利要求6所述的能够抑制幽门螺杆菌的漱口水的制备方法 ,其特征在于,所述步骤(4)中真空干燥的温度为55-65℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410026382.9A CN117530894B (zh) | 2024-01-09 | 2024-01-09 | 一种能够抑制幽门螺杆菌的漱口水及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410026382.9A CN117530894B (zh) | 2024-01-09 | 2024-01-09 | 一种能够抑制幽门螺杆菌的漱口水及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117530894A true CN117530894A (zh) | 2024-02-09 |
CN117530894B CN117530894B (zh) | 2024-05-17 |
Family
ID=89790331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410026382.9A Active CN117530894B (zh) | 2024-01-09 | 2024-01-09 | 一种能够抑制幽门螺杆菌的漱口水及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117530894B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08119872A (ja) * | 1994-10-18 | 1996-05-14 | Otsuka Pharmaceut Co Ltd | ヘリコバクター・ピロリに対する生薬組成物 |
US20080255498A1 (en) * | 2005-08-25 | 2008-10-16 | Houle Philip R | Sensitizer Solutions, Systems, and Methods of Use |
US20110319485A1 (en) * | 2010-06-24 | 2011-12-29 | Yushen Biotechnology & Medical Co, Ltd. | Composition Having Anti-Helicobacter Pylori Activity And Its Application To Inhibit Helicobacter Pylori |
US20130330116A1 (en) * | 2010-07-30 | 2013-12-12 | Sarita Mello | Mouthwash formulations for use with toothbrush delivery device |
WO2016106313A1 (en) * | 2014-12-23 | 2016-06-30 | Kiromic, Llc | Oral care compositions |
CN110636887A (zh) * | 2017-05-17 | 2019-12-31 | 高露洁-棕榄公司 | 口腔护理组合物和使用方法 |
CN112316123A (zh) * | 2020-12-03 | 2021-02-05 | 滁州向日葵药业有限公司 | 一种抗幽门螺杆菌感染的中药组合物及其制备方法与应用 |
CN113975206A (zh) * | 2021-11-22 | 2022-01-28 | 江苏罗来雅实业股份有限公司 | 一种抑制幽门螺旋杆菌的漱口水及其制作方法 |
CN114983896A (zh) * | 2022-06-29 | 2022-09-02 | 上海飞象健康科技有限公司 | 一种漱口水及其制备方法 |
CN115068383A (zh) * | 2022-07-05 | 2022-09-20 | 深圳市迈特智能有限公司 | 一种漱口水及其制备方法 |
-
2024
- 2024-01-09 CN CN202410026382.9A patent/CN117530894B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08119872A (ja) * | 1994-10-18 | 1996-05-14 | Otsuka Pharmaceut Co Ltd | ヘリコバクター・ピロリに対する生薬組成物 |
US20080255498A1 (en) * | 2005-08-25 | 2008-10-16 | Houle Philip R | Sensitizer Solutions, Systems, and Methods of Use |
US20110319485A1 (en) * | 2010-06-24 | 2011-12-29 | Yushen Biotechnology & Medical Co, Ltd. | Composition Having Anti-Helicobacter Pylori Activity And Its Application To Inhibit Helicobacter Pylori |
US20130330116A1 (en) * | 2010-07-30 | 2013-12-12 | Sarita Mello | Mouthwash formulations for use with toothbrush delivery device |
WO2016106313A1 (en) * | 2014-12-23 | 2016-06-30 | Kiromic, Llc | Oral care compositions |
CN110636887A (zh) * | 2017-05-17 | 2019-12-31 | 高露洁-棕榄公司 | 口腔护理组合物和使用方法 |
CN112316123A (zh) * | 2020-12-03 | 2021-02-05 | 滁州向日葵药业有限公司 | 一种抗幽门螺杆菌感染的中药组合物及其制备方法与应用 |
CN113975206A (zh) * | 2021-11-22 | 2022-01-28 | 江苏罗来雅实业股份有限公司 | 一种抑制幽门螺旋杆菌的漱口水及其制作方法 |
CN114983896A (zh) * | 2022-06-29 | 2022-09-02 | 上海飞象健康科技有限公司 | 一种漱口水及其制备方法 |
CN115068383A (zh) * | 2022-07-05 | 2022-09-20 | 深圳市迈特智能有限公司 | 一种漱口水及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN117530894B (zh) | 2024-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102178844A (zh) | 一种治疗牙龈肿痛的口腔中药制剂及其制备方法 | |
US20120288454A1 (en) | Dental protection toothpaste composition | |
CN108464963A (zh) | 一种用于口腔的组合物及其应用和制备方法 | |
CN105362295A (zh) | 一种治疗急慢性咽喉炎、口腔溃疡的美洲大蠊药物组合物及其制备方法 | |
CN110787078A (zh) | 一种含有甘草黄酮的牙膏及其制备方法和应用 | |
CN107929428B (zh) | 一种用于口腔的组合物及其应用 | |
WO2016010284A1 (ko) | 울금을 함유한 치약 조성물 및 그 제조 방법 | |
JP2000512270A (ja) | 単純ヘルペスの処置のための組成物および方法 | |
CN117530894B (zh) | 一种能够抑制幽门螺杆菌的漱口水及其制备方法 | |
US11806376B2 (en) | Pharmaceutical composition for treating oral ulcer and preparation method and application thereof | |
CN103610841B (zh) | 一种治疗竹鼠口腔炎的方法 | |
CN107913234A (zh) | 一种鹿茸草牙膏及其制备方法 | |
CN108066224A (zh) | 一种安胃疡牙膏及其制备方法 | |
CN106539727A (zh) | 杀菌护齿牙膏 | |
CN113332342A (zh) | 抗口腔幽门螺旋杆菌的中药提取物、口腔护理产品及其制备方法 | |
CN108785559B (zh) | 一种治疗呼吸道感染的药物及其制备方法 | |
CN107213244B (zh) | 一种有助于治疗牙龈出血的咀嚼片及其制备方法 | |
CN111184858A (zh) | 一种用于预防及治疗幽门螺杆菌制剂 | |
CN110692984A (zh) | 一种清除口腔异味的玫瑰花咀嚼片及其制备方法 | |
CN105125994A (zh) | 一种治疗口腔溃疡的中药 | |
CN110638891A (zh) | 一种止咳口服液 | |
CN114209638B (zh) | 一种用于制备牙膏的复方苦丁茶中药组合物及复方苦丁茶中药牙膏 | |
CN107648494A (zh) | 一种治疗牙龈炎及口腔溃疡中药含漱液及其制备方法 | |
CN113476574A (zh) | 一种治疗口腔问题的牙粉及其制备方法 | |
CN109432322A (zh) | 一种预防和治疗口腔溃疡的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |